ClinicalTrials.gg
CompletedNCT00274456Updated Nov 21, 2019Results posted

Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer

A Phase 2 interventional study of ABI-007 and Docetaxel in Metastatic Breast Cancer, sponsored by Celgene. Completed at 1 site in Ukraine. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-21.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
302
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms — 18 open to participants now, 22 under way, 2 of them phase 3. Albumin-Bound Paclitaxel · Breast Neoplasms.

Enrollment
16th of 108
302 · median 60
Started
2005
with 5 others
Phase 2
67 of 108
9 open now
Registered
9th of 108
by date
Lead sponsor
9 of 108
Celgene

Among the 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms, this one is the 16th largest by enrollment, is one of 6 that started in 2005, is one of 67 in phase 2, and was the 9th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

18 of the 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms are open now, in 10 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About Albumin-Bound Paclitaxel

Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms, or all of them as a file.
02

Study summary

This was an open-label study conducted comparing the toxicity and antitumor activity of ABI-007 (Abraxane®, nab®-paclitaxel) to docetaxel (Taxotere).

Read the detailed description

This was an open-label, randomized study to compare the following regimens with respect to toxicity and antitumor activity:

  • the maximum tolerated dose (MTD) of ABI-007 300 mg/m\^2 every 3 weeks;
  • ABI-007 100 mg/m\^2 administered weekly for 3 weeks with a 1 week rest;
  • ABI-007 150 mg/m\^2 administered weekly for 3 weeks with a 1 week rest;
  • the standard dose and schedule of Taxotere (100 mg/m\^2 every 3 weeks).
03

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

Keywords

  • Metastatic breast cancer, nab paclitaxel, docetaxel,
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients had to meet the following criteria to be eligible for the study:

  1. confirmed adenocarcinoma of the breast.
  2. No prior chemotherapy for breast cancer.
  3. Stage IV disease.
  4. (must have been ≥ 2.0 cm, except for pulmonary lesions that were well documented on CT scan that were ≥ 1.0 cm).
  5. At least 3 weeks since prior cytotoxic chemotherapy (patients should have recovered from all acute effects of such therapy.
  6. At least 4 weeks since radiotherapy, with full recovery. The measurable disease was completely outside the radiation portal or there was radiologic or clinical exam proof of progressive disease within the radiation portal.
  7. At least 4 weeks since major surgery, with full recovery.
  8. (ECOG) performance status 0-2.
  9. Age ≥18 years.
  10. Patient had the following blood counts at Baseline:

    • (ANC) ≥1.5*10\^9 cells/L
    • ≥100*10\^9 cells/L
    • (Hgb) ≥9 g/dL.
  11. Patient had the following baseline blood chemistry levels:

    • (AST [SGOT]), alanine aminotransferase (ALT [SGPT])≥2.5x (ULN) range
    • Total normal
    • Alkaline phosphatase ≥2.5x ULN (unless bone metastasis is present in the absence of liver metastasis)
    • Creatinine ≥1.5 mg/dL.
  12. Peripheral neuropathy Grade 0 or 1 by National Cancer Institute (NCI) (CTCAE).
  13. If female of , pregnancy test was negative (within 72 hours of the first dose of study drug).
  14. If fertile, the patient agreed to use an effective method to avoid pregnancy for the duration of the study.
  15. had been obtained.

Exclusion criteria

Exclusion Criteria:

Patients who met any of the following criteria were excluded from the study:

  1. Prior or adjuvant chemotherapy was allowed. No prior chemotherapy for disease was allowed. If a taxane was part of the adjuvant regimen, at least one year should have transpired since completion of taxane regimen.
  2. Cumulative life-time dose of doxorubicin >360 mg/m\^2. Doxorubicin was allowed as prior neo-adjuvant or adjuvant therapy but not for metastatic disease.
  3. Concurrent immunotherapy or hormonal therapy for breast cancer.
  4. Parenchymal , unless documented to be clinically and radiographically stable for at least 6 months after treatment.
  5. Serious intercurrent medical or psychiatric illness, including serious active infection.
  6. History of class II-IV congestive heart failure.
  7. History of other within the last 5 years which could affect the diagnosis or assessment of breast cancer.
  8. Patients who had received an drug within the previous 3 weeks.
  9. Patient was enrolled in a different clinical study in which investigational procedures were performed or investigational therapies were administered. Also, a patient was not permitted enroll in such clinical trials while participating in this study.
  10. Pregnant or nursing women
  11. Patients with prior to either Taxol or Taxotere.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
302 participants (actual)

Study arms

  • Experimental
    ABI-007 300 mg/m^2 q3w

    ABI-007 300 mg/m\^2 administered once every third week (q3w).

    Drug: ABI-007

  • Experimental
    ABI-007 100 mg/m^2 weekly

    ABI-007 100 mg/m\^2 once weekly for 3 weeks followed by 1 week of rest

    Drug: ABI-007

  • Experimental
    ABI-007 150 mg/m^2 weekly

    ABI-007 150 mg/m\^2 once weekly for 3 weeks followed by 1 week of rest

    Drug: ABI-007

  • Active comparator
    Docetaxel 100 mg/m^2, q3w

    Docetaxel (Taxotere) 100 mg/m\^2 administered once every third week (q3w).

    Drug: Docetaxel

Interventions

  • ABI-007 administered by intravenous infusion over 30 minutes at one of three different dosing levels (100, 150 or 300 mg/m\^2) with a treatment cycle length of either 3 or 4 weeks depending upon treatment arm assignment.

    Also known as: Abraxane®, nab®-paclitaxel

  • Docetaxel dosed q3w at 100 mg/m\^2

    Also known as: Taxotere

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Showing an Overall Response As Assessed by the Independent Radiology Reader and by the Investigator

    Percentage of participants who achieve an objective confirmed complete or partial overall response based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. A complete response (CR) is the disappearance of all known disease and no new sites or disease related symptoms. A partial response (PR) is \>= 30% decrease in the sum of the longest diameters of target lesion. PR was also recorded when all measurable disease has completely disappeared, but a non-measurable component (ie, ascites) is still present but not progressing. Overall response (ORR) = CR+PR.

    Time frame: Day 1 up to 95 weeks

Secondary outcomes

  1. Percentage of Participants With Stable Disease for ≥ 16 Weeks, or Complete or Partial Overall Response

    Known as the disease control rate, this outcome measures the percentage of participants with stable disease for 16 weeks or more, or had a confirmed complete or partial response (see outcome #1 for confirmed response definitions). Assessments made by independent radiology and by investigators are reported separately

    Time frame: Day 1 up to 95 weeks

  2. Kaplan-Meier Estimates for Progression-free Survival (PFS)

    PFS was defined as the time from the date of randomization to the start of disease progression (PD) or patient death (any cause), whichever occurred first. Patients without disease progression were censored at the last time the patient was known to be progression-free. Patients who initiated new anticancer therapy prior to documented progression or death were censored at the start of new therapy. Disease progression was assessed separately by investigators and by an independent radiologist. Both assessments are offered. Response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 (Therasse, 2000). PD for target lesions is defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.

    Time frame: Day 1 up to 95 weeks

  3. Kaplan-Meier Estimates for Duration of Response Based on Independent Radiology Assessment of Response and Progression

    Duration of response was measured as the progression-free survival on patients with confirmed response. The independent radiology assessment is offered here. Response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 (Therasse, 2000) and is defined in outcome #1. Progression-free survival is defined in outcome #3.

    Time frame: Day 1 - 95 weeks

  4. Kaplan-Meier Estimates for Duration of Response Based on Investigator Assessment of Response and Progression

    Duration of response was measured as the progression-free survival on patients with confirmed response. The investigator assessment is offered here. Response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 (Therasse, 2000) and is defined in outcome #1. Progression-free survival is defined in outcome #3.

    Time frame: Day 1 - 95 weeks

  5. Kaplan-Meier Estimate for Overall Survival (OS)

    Participant survival was defined as the date of randomization to the date of death. Participants that were alive at the time of analysis were censored at the last known time that the participant was alive. The final analysis of mature overall survival was conducted after 2 years of follow-up (data cutoff date 31 Jan 2010).

    Time frame: Day 1 to 221 weeks

  6. Participants With Treatment-Emergent, Treatment-Related Adverse Events

    Summary of participants who had treatment-emergent that were treatment-related in the opinion of the investigator, and summarized in a variety of categories. The National Cancer Institute (NCI)'s Common Terminology Criteria for AEs (CTCAE) was used to grade AE severity: severity grade 3= severe and undesirable AE. Severity grade 4= life-threatening or disabling AE. Severity grade 5 = death.

    Time frame: Day 1 up to 125 weeks

Other outcomes

  1. Nadir of Myelosuppression (Over All Cycles) as Measured by Absolute Neutrophils (ANC), White Blood Cells (WBC) and Platelet Counts

    Maximal degree of myelosuppression is represented by the nadir in absolute neutrophil (ANC), white blood cell (WBC), and platelet measurements over all treatment cycles.

    Time frame: Day 1 up to 125 weeks

  2. Nadir of Myelosuppression (Over All Cycles) as Measured by Hemoglobin (Hb) Counts

    Maximal degree of myelosuppression is represented by the nadir in hemoglobin (Hb) measurements over all treatment cycles.

    Time frame: Day 1 up to 125 weeks

07

Results

Posted Jul 2, 2013

Participant flow

Participant flow — Overall Study
MilestoneABI-007 300 mg/m^2 q3wABI-007 100 mg/m^2 WeeklyABI-007 150 mg/m^2 WeeklyDocetaxel 100 mg/m^2 q3w
Started76767474
At least one response assessment73767370
Completed39493929
Not completed37273545
Withdrew: Still on treatment2351
Withdrew: Unacceptable toxicity1051216
Withdrew: Adverse event0122
Withdrew: Physician decision75613
Withdrew: Lost to follow-up0010
Withdrew: Withdrawal by subject1813913

Outcome measures

PrimaryPercentage of Participants Showing an Overall Response As Assessed by the Independent Radiology Reader and by the Investigator

Percentage of participants who achieve an objective confirmed complete or partial overall response based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. A complete response (CR) is the disappearance of all known disease and no new sites or disease related symptoms. A partial response (PR) is \>= 30% decrease in the sum of the longest diameters of target lesion. PR was also recorded when all measurable disease has completely disappeared, but a non-measurable component (ie, ascites) is still present but not progressing. Overall response (ORR) = CR+PR.

Time frame:
Day 1 up to 95 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Showing an Overall Response As Assessed by the Independent Radiology Reader and by the Investigator
percentage of participantsABI-007 300 mg/m^2 q3wABI-007 100 mg/m^2 WeeklyABI-007 150 mg/m^2 WeeklyDocetaxel 100 mg/m^2 q3w
Independent reader assessed ORR37 (26.0 to 47.7)45 (33.6 to 55.9)49 (37.3 to 60.0)35 (24.3 to 46.0)
Investigator assessed ORR46 (34.8 to 57.3)63 (52.3 to 74.0)74 (64.4 to 84.3)39 (28.1 to 50.3)
Statistical analysis
  • ABI-007 300 mg/m^2 q3w vs ABI-007 100 mg/m^2 Weekly vs ABI-007 150 mg/m^2 Weekly vs Docetaxel 100 mg/m^2 q3w · Cochran-Mantel-Haenszel · p = 0.224 (A step-down approach was used to compare treatment regimens. First an overall "test of treatment difference" (a 3-degree-of -freedom test) was performed. Pairwise comparisons were performed only if this test was significant.)CMH test was stratified by study site
  • ABI-007 300 mg/m^2 q3w vs ABI-007 100 mg/m^2 Weekly vs ABI-007 150 mg/m^2 Weekly vs Docetaxel 100 mg/m^2 q3w · Cochran-Mantel-Haenszel · p = <0.001 (A step-down approach was used to compare treatment regimens. First an overall "test of treatment difference" (a 3-degree-of -freedom test) was performed. Pairwise comparisons were performed only if this test was significant.)CMH was stratified by study site
  • ABI-007 300 mg/m^2 q3w vs ABI-007 150 mg/m^2 Weekly · Cochran-Mantel-Haenszel · p = 0.002CMH test was stratified by study site
  • ABI-007 150 mg/m^2 Weekly vs Docetaxel 100 mg/m^2 q3w · Cochran-Mantel-Haenszel · p = <0.001CMH test was stratified by study site.
  • ABI-007 300 mg/m^2 q3w vs Docetaxel 100 mg/m^2 q3w · Cochran-Mantel-Haenszel · p = >0.05CMH test was stratified by study site
  • ABI-007 300 mg/m^2 q3w vs ABI-007 100 mg/m^2 Weekly · Cochran-Mantel-Haenszel · p = 0.024CMH test was stratified by study site.
  • ABI-007 100 mg/m^2 Weekly vs ABI-007 150 mg/m^2 Weekly · Cochran-Mantel-Haenszel · p = 0.099CMH test was stratified by study site.
  • ABI-007 100 mg/m^2 Weekly vs Docetaxel 100 mg/m^2 q3w · Cochran-Mantel-Haenszel · p = 0.002CMH test was stratified by study site.
SecondaryPercentage of Participants With Stable Disease for ≥ 16 Weeks, or Complete or Partial Overall Response

Known as the disease control rate, this outcome measures the percentage of participants with stable disease for 16 weeks or more, or had a confirmed complete or partial response (see outcome #1 for confirmed response definitions). Assessments made by independent radiology and by investigators are reported separately

Time frame:
Day 1 up to 95 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Stable Disease for ≥ 16 Weeks, or Complete or Partial Overall Response
percentage of participantsABI-007 300 mg/m^2 q3wABI-007 100 mg/m^2 WeeklyABI-007 150 mg/m^2 WeeklyDocetaxel 100 mg/m^2 q3w
Independent Assessed SD Disease Control68 (58.0 to 78.9)75 (65.3 to 84.7)80 (70.6 to 88.9)58 (46.9 to 69.3)
Investigator Assessed Disease Control72 (62.3 to 82.4)83 (74.4 to 91.4)91 (83.9 to 97.2)69 (58.4 to 79.5)
Statistical analysis
  • ABI-007 300 mg/m^2 q3w vs ABI-007 100 mg/m^2 Weekly vs ABI-007 150 mg/m^2 Weekly vs Docetaxel 100 mg/m^2 q3w · Cochran-Mantel-Haenszel · p = 0.027CMH test was stratified by study site.
  • ABI-007 100 mg/m^2 Weekly vs Docetaxel 100 mg/m^2 q3w · Cochran-Mantel-Haenszel · p = 0.009CMH test was stratified by study site.
  • ABI-007 150 mg/m^2 Weekly vs Docetaxel 100 mg/m^2 q3w · Cochran-Mantel-Haenszel · p = 0.017CMH test was stratified by study site.
  • ABI-007 300 mg/m^2 q3w vs Docetaxel 100 mg/m^2 q3w · Cochran-Mantel-Haenszel · p = >0.05CMH test was stratified by study site.
  • ABI-007 100 mg/m^2 Weekly vs ABI-007 150 mg/m^2 Weekly · Cochran-Mantel-Haenszel · p = >0.05CMH test was stratified by study site.
  • ABI-007 300 mg/m^2 q3w vs ABI-007 100 mg/m^2 Weekly · Cochran-Mantel-Haenszel · p = >0.05CMH test was stratified by study site.
  • ABI-007 300 mg/m^2 q3w vs ABI-007 150 mg/m^2 Weekly · Cochran-Mantel-Haenszel · p = 0.085CMH test was stratified by study site.
  • ABI-007 300 mg/m^2 q3w vs ABI-007 100 mg/m^2 Weekly vs ABI-007 150 mg/m^2 Weekly vs Docetaxel 100 mg/m^2 q3w · Cochran-Mantel-Haenszel · p = 0.007 (A step-down approach was used to compare treatment regimens. First an overall "test of treatment difference" (a 3-degree-of -freedom test) was performed. Pairwise comparison was performed only if this test was significant.)CMH test was stratified by study site.
  • ABI-007 300 mg/m^2 q3w vs Docetaxel 100 mg/m^2 q3w · Cochran-Mantel-Haenszel · p = >0.05CMH test was stratified by study site.
  • ABI-007 100 mg/m^2 Weekly vs Docetaxel 100 mg/m^2 q3w · Cochran-Mantel-Haenszel · p = 0.009CMH test was stratified by study site.
  • ABI-007 150 mg/m^2 Weekly vs Docetaxel 100 mg/m^2 q3w · Cochran-Mantel-Haenszel · p = 0.005CMH test was stratified by study site.
  • ABI-007 100 mg/m^2 Weekly vs ABI-007 150 mg/m^2 Weekly · Cochran-Mantel-Haenszel · p = >0.05CMH test was stratified by study site.
  • ABI-007 300 mg/m^2 q3w vs ABI-007 100 mg/m^2 Weekly · Cochran-Mantel-Haenszel · p = 0.098CMH test was stratified by study site.
  • ABI-007 300 mg/m^2 q3w vs ABI-007 150 mg/m^2 Weekly · Cochran-Mantel-Haenszel · p = 0.014CMH test was stratified by study site.
SecondaryKaplan-Meier Estimates for Progression-free Survival (PFS)

PFS was defined as the time from the date of randomization to the start of disease progression (PD) or patient death (any cause), whichever occurred first. Patients without disease progression were censored at the last time the patient was known to be progression-free. Patients who initiated new anticancer therapy prior to documented progression or death were censored at the start of new therapy. Disease progression was assessed separately by investigators and by an independent radiologist. Both assessments are offered. Response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 (Therasse, 2000). PD for target lesions is defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.

Time frame:
Day 1 up to 95 weeks
Reported as:
Median · months
Kaplan-Meier Estimates for Progression-free Survival (PFS)
monthsABI-007 300 mg/m^2 q3wABI-007 100 mg/m^2 WeeklyABI-007 150 mg/m^2 WeeklyDocetaxel 100 mg/m^2 q3w
Independent Assessment for PFS11.0 (7.3 to 15.0)12.8 (9.0 to 14.7)12.9 (10.9 to 16.6)7.5 (7.2 to 9.0)
Investigator Assessment for PFS10.9 (8.9 to 14.6)7.5 (7.2 to 9.3)14.6 (10.0 to 18.9)7.8 (6.3 to 11.0)
Statistical analysis
  • ABI-007 300 mg/m^2 q3w vs ABI-007 100 mg/m^2 Weekly vs ABI-007 150 mg/m^2 Weekly vs Docetaxel 100 mg/m^2 q3w · Log Rank · p = 0.0498 (A step-down approach was used to compare treatment regimens. First an overall "test of treatment difference" (a 3-degree-of -freedom test) was performed. Pairwise comparisons were performed only if this test was significant.)
  • ABI-007 100 mg/m^2 Weekly vs Docetaxel 100 mg/m^2 q3w · Log Rank · p = 0.0524 · Hazard ratio (hr): 0.607
  • ABI-007 150 mg/m^2 Weekly vs Docetaxel 100 mg/m^2 q3w · Log Rank · p = 0.0065 · Hazard ratio (hr): 0.495
  • ABI-007 300 mg/m^2 q3w vs ABI-007 100 mg/m^2 Weekly · Log Rank · p = >0.05
  • ABI-007 300 mg/m^2 q3w vs ABI-007 150 mg/m^2 Weekly · Log Rank · p = >0.05
  • ABI-007 100 mg/m^2 Weekly vs ABI-007 150 mg/m^2 Weekly · Log Rank · p = >0.05
  • ABI-007 300 mg/m^2 q3w vs Docetaxel 100 mg/m^2 q3w · Log Rank · p = >0.05
  • ABI-007 300 mg/m^2 q3w vs ABI-007 100 mg/m^2 Weekly vs ABI-007 150 mg/m^2 Weekly vs Docetaxel 100 mg/m^2 q3w · Log Rank · p = 0.008 (A step-down approach was used to compare treatment regimens. First an overall "test of treatment difference" (a 3-degree-of -freedom test) was performed. Pairwise comparisons was performed only if this test was significant.)
  • ABI-007 300 mg/m^2 q3w vs Docetaxel 100 mg/m^2 q3w · Log Rank · p = >0.05
  • ABI-007 100 mg/m^2 Weekly vs Docetaxel 100 mg/m^2 q3w · Log Rank · p = >0.05
  • ABI-007 150 mg/m^2 Weekly vs Docetaxel 100 mg/m^2 q3w · Log Rank · p = 0.012 · Hazard ratio (hr): 0.568
  • ABI-007 100 mg/m^2 Weekly vs ABI-007 150 mg/m^2 Weekly · Log Rank · p = 0.001 · Hazard ratio (hr): 1.972
  • ABI-007 300 mg/m^2 q3w vs ABI-007 100 mg/m^2 Weekly · Log Rank · p = 0.076 · Hazard ratio (hr): 0.702
  • ABI-007 300 mg/m^2 q3w vs ABI-007 150 mg/m^2 Weekly · Log Rank · p = >0.05
SecondaryKaplan-Meier Estimates for Duration of Response Based on Independent Radiology Assessment of Response and Progression

Duration of response was measured as the progression-free survival on patients with confirmed response. The independent radiology assessment is offered here. Response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 (Therasse, 2000) and is defined in outcome #1. Progression-free survival is defined in outcome #3.

Time frame:
Day 1 - 95 weeks
Reported as:
Median · months
Kaplan-Meier Estimates for Duration of Response Based on Independent Radiology Assessment of Response and Progression
monthsABI-007 300 mg/m^2 q3wABI-007 100 mg/m^2 WeeklyABI-007 150 mg/m^2 WeeklyDocetaxel 100 mg/m^2 q3w
Kaplan-Meier Estimates for Duration of Response Based on Independent Radiology Assessment of Response and Progression13.0 (11.2 to 23.9)13.2 (11.3 to 14.9)15.1 (10.9 to 16.7)9.0 (7.5 to 14.8)
Statistical analysis
  • ABI-007 300 mg/m^2 q3w vs ABI-007 100 mg/m^2 Weekly vs ABI-007 150 mg/m^2 Weekly vs Docetaxel 100 mg/m^2 q3w · Log Rank · p = >0.05 (A step-down approach was used to compare treatment regimens. First an overall "test of treatment difference" (a 3-degree-of -freedom test) was performed. Pairwise comparisons was performed only if this test was significant.)
SecondaryKaplan-Meier Estimates for Duration of Response Based on Investigator Assessment of Response and Progression

Duration of response was measured as the progression-free survival on patients with confirmed response. The investigator assessment is offered here. Response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 (Therasse, 2000) and is defined in outcome #1. Progression-free survival is defined in outcome #3.

Time frame:
Day 1 - 95 weeks
Reported as:
Median · months
Kaplan-Meier Estimates for Duration of Response Based on Investigator Assessment of Response and Progression
monthsABI-007 300 mg/m^2 q3wABI-007 100 mg/m^2 WeeklyABI-007 150 mg/m^2 WeeklyDocetaxel 100 mg/m^2 q3w
Kaplan-Meier Estimates for Duration of Response Based on Investigator Assessment of Response and Progression12.9 (10.3 to 19.4)9.2 (7.4 to 12.4)14.8 (12.8 to 19.2)15.1 (11.0 to 17.6)
Statistical analysis
  • ABI-007 300 mg/m^2 q3w vs ABI-007 100 mg/m^2 Weekly vs ABI-007 150 mg/m^2 Weekly vs Docetaxel 100 mg/m^2 q3w · Log Rank · p = 0.013 (A step-down approach was used to compare treatment regimens. First an overall "test of treatment difference" (a 3-degree-of -freedom test) was performed. Pairwise comparisons was performed only if this test was significant.)
  • ABI-007 100 mg/m^2 Weekly vs Docetaxel 100 mg/m^2 q3w · Log Rank · p = 0.022
  • ABI-007 150 mg/m^2 Weekly vs Docetaxel 100 mg/m^2 q3w · Log Rank · p = >0.05
  • ABI-007 300 mg/m^2 q3w vs Docetaxel 100 mg/m^2 q3w · Log Rank · p = >0.05
  • ABI-007 100 mg/m^2 Weekly vs ABI-007 150 mg/m^2 Weekly · Log Rank · p = 0.005
  • ABI-007 300 mg/m^2 q3w vs ABI-007 100 mg/m^2 Weekly · Log Rank · p = >0.05
  • ABI-007 300 mg/m^2 q3w vs ABI-007 150 mg/m^2 Weekly · Log Rank · p = >0.05
SecondaryKaplan-Meier Estimate for Overall Survival (OS)

Participant survival was defined as the date of randomization to the date of death. Participants that were alive at the time of analysis were censored at the last known time that the participant was alive. The final analysis of mature overall survival was conducted after 2 years of follow-up (data cutoff date 31 Jan 2010).

Time frame:
Day 1 to 221 weeks
Reported as:
Median · months
Kaplan-Meier Estimate for Overall Survival (OS)
monthsABI-007 300 mg/m^2 q3wABI-007 100 mg/m^2 WeeklyABI-007 150 mg/m^2 WeeklyDocetaxel 100 mg/m^2 q3w
Kaplan-Meier Estimate for Overall Survival (OS)27.7 (21.7 to 38.9)22.2 (16.9 to 29.4)33.8 (29.1 to 41.3)26.6 (19.0 to 31.3)
Statistical analysis
  • ABI-007 300 mg/m^2 q3w vs ABI-007 100 mg/m^2 Weekly vs ABI-007 150 mg/m^2 Weekly vs Docetaxel 100 mg/m^2 q3w · Log Rank · p = 0.047 (A step-down approach was used to compare treatment regimens. First an overall "test of treatment difference" (a 3-degree-of -freedom test) was performed. Pairwise comparisons were performed only if this test was significant.)
  • ABI-007 300 mg/m^2 q3w vs Docetaxel 100 mg/m^2 q3w · Log Rank · p = >0.05
  • ABI-007 100 mg/m^2 Weekly vs Docetaxel 100 mg/m^2 q3w · Log Rank · p = >0.05
  • ABI-007 150 mg/m^2 Weekly vs Docetaxel 100 mg/m^2 q3w · Log Rank · p = >0.05
  • ABI-007 300 mg/m^2 q3w vs ABI-007 100 mg/m^2 Weekly · Log Rank · p = 0.069 · Hazard ratio (hr): 0.686
  • ABI-007 300 mg/m^2 q3w vs ABI-007 150 mg/m^2 Weekly · Log Rank · p = >0.05
  • ABI-007 100 mg/m^2 Weekly vs ABI-007 150 mg/m^2 Weekly · Log Rank · p = 0.008 · Hazard ratio (hr): 1.740
Other pre-specifiedNadir of Myelosuppression (Over All Cycles) as Measured by Absolute Neutrophils (ANC), White Blood Cells (WBC) and Platelet Counts

Maximal degree of myelosuppression is represented by the nadir in absolute neutrophil (ANC), white blood cell (WBC), and platelet measurements over all treatment cycles.

Time frame:
Day 1 up to 125 weeks
Reported as:
Mean · 10^9/L
Nadir of Myelosuppression (Over All Cycles) as Measured by Absolute Neutrophils (ANC), White Blood Cells (WBC) and Platelet Counts
10^9/LABI-007 300 mg/m^2 q3wABI-007 100 mg/m^2 WeeklyABI-007 150 mg/m^2 WeeklyDocetaxel 100 mg/m^2 q3w
ANC1.21 ± 1.0041.51 ± 0.9601.11 ± 0.6280.38 ± 0.339
WBC2.88 ± 1.1873.15 ± 1.2282.68 ± 0.8171.60 ± 0.726
Platelet182.1 ± 59.16192.1 ± 57.82172.6 ± 46.39161.8 ± 49.06
SecondaryParticipants With Treatment-Emergent, Treatment-Related Adverse Events

Summary of participants who had treatment-emergent that were treatment-related in the opinion of the investigator, and summarized in a variety of categories. The National Cancer Institute (NCI)'s Common Terminology Criteria for AEs (CTCAE) was used to grade AE severity: severity grade 3= severe and undesirable AE. Severity grade 4= life-threatening or disabling AE. Severity grade 5 = death.

Time frame:
Day 1 up to 125 weeks
Reported as:
Number · participants
Participants With Treatment-Emergent, Treatment-Related Adverse Events
participantsABI-007 300 mg/m^2 q3wABI-007 100 mg/m^2 WeeklyABI-007 150 mg/m^2 WeeklyDocetaxel 100 mg/m^2 q3w
>= 1 adverse event (AE)75757373
>=1 treatment-related AE74727372
>=1 serious AE14121156
>=1 treatment-related serious AE135855
>=1 severe (grade 3-5) treatment-related AE47304971
Grade 3-5 Neutropenia33193368
Grade 3-5 Febrile neutropenia1118
Grade 3-5 Sensory neuropathy167169
>=1 AE with outcome of death0122
>=1 treatment-related AE with outcome of death0002
>=1 treatment-related AE drug discontinued1051216
>=1 treatment-related AE drug dosage reduced14133521
>=1 treatment-related AE drug interrupted1101
Other pre-specifiedNadir of Myelosuppression (Over All Cycles) as Measured by Hemoglobin (Hb) Counts

Maximal degree of myelosuppression is represented by the nadir in hemoglobin (Hb) measurements over all treatment cycles.

Time frame:
Day 1 up to 125 weeks
Reported as:
Mean · g/L
Nadir of Myelosuppression (Over All Cycles) as Measured by Hemoglobin (Hb) Counts
g/LABI-007 300 mg/m^2 q3wABI-007 100 mg/m^2 WeeklyABI-007 150 mg/m^2 WeeklyDocetaxel 100 mg/m^2 q3w
Nadir of Myelosuppression (Over All Cycles) as Measured by Hemoglobin (Hb) Counts112.1 ± 10.58106.7 ± 10.72105.6 ± 11.31107.1 ± 13.39

Adverse events

Collected over Day 1 up to 125 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ABI-007 300 mg/m^2 q3w—14/76 (18.4%)75/76 (98.7%)
ABI-007 100 mg/m^2 Weekly—12/76 (15.8%)75/76 (98.7%)
ABI-007 150 mg/m^2 Weekly—11/74 (14.9%)73/74 (98.6%)
Docetaxel 100 mg/m^2 q3w—56/74 (75.7%)73/74 (98.6%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventABI-007 300 mg/m^2 q3wABI-007 100 mg/m^2 WeeklyABI-007 150 mg/m^2 WeeklyDocetaxel 100 mg/m^2 q3w
NeutropeniaBlood and lymphatic system disorders10/762/764/7452/74
Febrile neutropeniaBlood and lymphatic system disorders1/761/761/748/74
ErysipelasInfections and infestations0/762/760/741/74
AnaemiaBlood and lymphatic system disorders0/760/761/740/74
ThrombocytopeniaBlood and lymphatic system disorders0/760/760/741/74
DiarrhoeaGastrointestinal disorders0/760/760/741/74
GastritisGastrointestinal disorders0/760/760/741/74
Chronic sinusitisInfections and infestations0/760/761/740/74
Cardiopulmonary failureCardiac disorders0/761/761/740/74
Body temperature increasedInvestigations0/760/760/741/74
Most frequent other events
Showing 10 of 43
Most frequent other events
EventABI-007 300 mg/m^2 q3wABI-007 100 mg/m^2 WeeklyABI-007 150 mg/m^2 WeeklyDocetaxel 100 mg/m^2 q3w
AlopeciaSkin and subcutaneous tissue disorders51/7659/7659/7452/74
NeutropeniaBlood and lymphatic system disorders31/7622/7638/7455/74
Peripheral sensory neuropathyNervous system disorders33/7630/7645/7429/74
AstheniaGeneral disorders22/7618/7622/7430/74
ArthralgiaMusculoskeletal and connective tissue disorders26/7616/7626/7417/74
Nail disorderSkin and subcutaneous tissue disorders3/768/7620/7410/74
NeuropathyNervous system disorders19/7610/769/7415/74
Oedema peripheralGeneral disorders7/7613/7616/7418/74
Performance status decreasedGeneral disorders10/7618/7610/7414/74
LeukopeniaBlood and lymphatic system disorders9/763/764/7417/74

Baseline characteristics

Age, Continuous
Age, Continuous(years)ABI-007 300 mg/m^2 q3wABI-007 100 mg/m^2 WeeklyABI-007 150 mg/m^2Docetaxel 100 mg/m^2 q3wTotal
Mean51.7 ± 9.4755.4 ± 9.5953.3 ± 9.1455.4 ± 11.5753.9 ± 10.05
Age, Customized
Age, Customized(Participants)ABI-007 300 mg/m^2 q3wABI-007 100 mg/m^2 WeeklyABI-007 150 mg/m^2Docetaxel 100 mg/m^2 q3wTotal
>=65 years914101952
<65 years67626455248
Sex: Female, Male
Sex: Female, Male(Participants)ABI-007 300 mg/m^2 q3wABI-007 100 mg/m^2 WeeklyABI-007 150 mg/m^2Docetaxel 100 mg/m^2 q3wTotal
Female76767474300
Male00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ABI-007 300 mg/m^2 q3wABI-007 100 mg/m^2 WeeklyABI-007 150 mg/m^2Docetaxel 100 mg/m^2 q3wTotal
White, Non-Hispanic, Non-Latino74757474297
White, Hispanic or Latino21003
Weight
Weight(Kg)ABI-007 300 mg/m^2 q3wABI-007 100 mg/m^2 WeeklyABI-007 150 mg/m^2Docetaxel 100 mg/m^2 q3wTotal
Mean72.56 ± 12.66873.64 ± 14.67076.24 ± 13.43775.99 ± 14.03474.59 ± 13.742
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)ABI-007 300 mg/m^2 q3wABI-007 100 mg/m^2 WeeklyABI-007 150 mg/m^2Docetaxel 100 mg/m^2 q3wTotal
0 (fully active)34332428119
1 (restrictive but ambulatory)35394544163
2 (ambulatory but unable to work)745218
3 (limited self-care) + 4 (completely disabled)00000
Menopausal Status
Menopausal Status(Participants)ABI-007 300 mg/m^2 q3wABI-007 100 mg/m^2 WeeklyABI-007 150 mg/m^2Docetaxel 100 mg/m^2 q3wTotal
Pre-menopausal2614211273
Post-menopausal49625360224
Unknown10023
Physician Assessment of Sensory Neuropathy
Physician Assessment of Sensory Neuropathy(Participants)ABI-007 300 mg/m^2 q3wABI-007 100 mg/m^2 WeeklyABI-007 150 mg/m^2Docetaxel 100 mg/m^2 q3wTotal
Grade 067706567269
Grade 1969731

5 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Study Sites in Russia and the Ukraine
    Kiev, 01021, Ukraine
09

References and documents

Publications

  • O'Shaughnessy J, Gradishar WJ, Bhar P, Iglesias J. Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis. Breast Cancer Res Treat. 2013 Apr;138(3):829-37. doi: 10.1007/s10549-013-2447-8. Epub 2013 Apr 6. PubMed 23563958 ↗
  • Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, Bhar P. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol. 2009 Aug 1;27(22):3611-9. doi: 10.1200/JCO.2008.18.5397. Epub 2009 May 26. Erratum In: J Clin Oncol. 2011 Jul 1;29(19):2739. PubMed 19470941 ↗
  • Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, Bhar P, McGuire JR, Iglesias J. Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival. Clin Breast Cancer. 2012 Oct;12(5):313-21. doi: 10.1016/j.clbc.2012.05.001. Epub 2012 Jun 23. PubMed 22728026 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2005 to primary completion in Mar 2008, 28 months.

Results were first posted in Jul 2013, 5 years 4 months after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 28 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2006
First posted
Jan 11, 2006
StartActual
Nov 1, 2005
Primary completionActual
Mar 1, 2008
CompletionActual
Jul 1, 2011
Results first posted
Jul 2, 2013
Last update
Nov 21, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00274456
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Jan 11, 2006
Start date
Nov 1, 2005
Primary completion
Mar 1, 2008
Completion
Jul 1, 2011
Results posted
Jul 2, 2013
Last update
Nov 21, 2019

Study contacts

Jose Iglesias, MD
study chair · Abraxis BioScience, LLC, a wholly owned subsidiary of Celgene Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albumin-Bound Paclitaxel

Start the discussion